Baxter Posts 1Q Loss, Backs 2026 Growth Views

Dow Jones

Apr 30

By Rob Curran

Baxter International posted a first-quarter loss on higher expenses and one-off items but the health-care conglomerate's sales growth exceeded Wall Street expectations and it backed 2026 growth projections.

The maker of medical supplies and pharmaceuticals posted a loss of $15 million, or 3 cents a share, in contrast to a profit of $126 million, or 25 cents a share, a year earlier.

Stripping out certain one-off items, the company logged adjusted earnings of 37 cents a share, besting the mean analyst projection of 31 cents a share, as per FactSet.

Sales rose 3% to $2.7 billion, exceeding the average analyst target of $2.62 billion.

Medical products and therapies rose 2% to $1.3 billion; healthcare systems and technologies sales were more or less flat at about $705 million; while pharmaceutical sales rose 7% to $621 million.

The company reiterated its forecast for 2026 adjusted earnings from continuing operations of $1.85-to-$2.05 a share, in line with the average Wall Street target of $1.90 a share.

Baxter also backed its projection for sales from continuing operations to be flat to up 1% for the year.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

April 30, 2026 08:21 ET (12:21 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2631632349"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631632349\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631632349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631632349","market":"hk","top_or_hot":-1,"title":"Baxter Posts 1Q Loss, Backs 2026 Growth Views","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Baxter International posted a first-quarter loss on higher expenses and one-off items but the health-care conglomerate's sales growth exceeded Wall Street expectations and it backed 2026 growth projections. \n</p>\n<p>\n  The maker of medical supplies and pharmaceuticals posted a loss of $15 million, or 3 cents a share, in contrast to a profit of $126 million, or 25 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, the company logged adjusted earnings of 37 cents a share, besting the mean analyst projection of 31 cents a share, as per FactSet. \n</p>\n<p>\n  Sales rose 3% to $2.7 billion, exceeding the average analyst target of $2.62 billion. \n</p>\n<p>\n  Medical products and therapies rose 2% to $1.3 billion; healthcare systems and technologies sales were more or less flat at about $705 million; while pharmaceutical sales rose 7% to $621 million. \n</p>\n<p>\n  The company reiterated its forecast for 2026 adjusted earnings from continuing operations of $1.85-to-$2.05 a share, in line with the average Wall Street target of $1.90 a share. \n</p>\n<p>\n  Baxter also backed its projection for sales from continuing operations to be flat to up 1% for the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baxter Posts 1Q Loss, Backs 2026 Growth Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaxter Posts 1Q Loss, Backs 2026 Growth Views\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-30 20:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Baxter International posted a first-quarter loss on higher expenses and one-off items but the health-care conglomerate's sales growth exceeded Wall Street expectations and it backed 2026 growth projections. \n</p>\n<p>\n  The maker of medical supplies and pharmaceuticals posted a loss of $15 million, or 3 cents a share, in contrast to a profit of $126 million, or 25 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, the company logged adjusted earnings of 37 cents a share, besting the mean analyst projection of 31 cents a share, as per FactSet. \n</p>\n<p>\n  Sales rose 3% to $2.7 billion, exceeding the average analyst target of $2.62 billion. \n</p>\n<p>\n  Medical products and therapies rose 2% to $1.3 billion; healthcare systems and technologies sales were more or less flat at about $705 million; while pharmaceutical sales rose 7% to $621 million. \n</p>\n<p>\n  The company reiterated its forecast for 2026 adjusted earnings from continuing operations of $1.85-to-$2.05 a share, in line with the average Wall Street target of $1.90 a share. \n</p>\n<p>\n  Baxter also backed its projection for sales from continuing operations to be flat to up 1% for the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2026 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2098885051.SGD","symbol_name":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631632349","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631632349","pubTimestamp":1777551660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Baxter International posted a first-quarter loss on higher expenses and one-off items but the health-care conglomerate's sales growth exceeded Wall Street expectations and it backed 2026 growth projections.The maker of medical supplies and pharmaceuticals posted a loss of $15 million, or 3 cents a share, in contrast to a profit of $126 million, or 25 cents a share, a year earlier.Stripping out certain one-off items, the company logged adjusted earnings of 37 cents a share, besting the mean analyst projection of 31 cents a share, as per FactSet.Sales rose 3% to $2.7 billion, exceeding the average analyst target of $2.62 billion.Medical products and therapies rose 2% to $1.3 billion; healthcare systems and technologies sales were more or less flat at about $705 million; while pharmaceutical sales rose 7% to $621 million.The company reiterated its forecast for 2026 adjusted earnings from continuing operations of $1.85-to-$2.05 a share, in line with the average Wall Street target of $1.90 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BAX":"百特国际","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4082":"医疗保健设备","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4504":"桥水持仓","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC"},"translate_title":"百特公布第一季度亏损，支持2026年增长观点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAX":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Baxter International posted a first-quarter loss on higher expenses and one-off items but the health-care conglomerate's sales growth exceeded Wall Street expectations and it backed 2026 growth projections. \n\n\n  The maker of medical supplies and pharmaceuticals posted a loss of $15 million, or 3 cents a share, in contrast to a profit of $126 million, or 25 cents a share, a year earlier. \n\n\n  Stripping out certain one-off items, the company logged adjusted earnings of 37 cents a share, besting the mean analyst projection of 31 cents a share, as per FactSet. \n\n\n  Sales rose 3% to $2.7 billion, exceeding the average analyst target of $2.62 billion. \n\n\n  Medical products and therapies rose 2% to $1.3 billion; healthcare systems and technologies sales were more or less flat at about $705 million; while pharmaceutical sales rose 7% to $621 million. \n\n\n  The company reiterated its forecast for 2026 adjusted earnings from continuing operations of $1.85-to-$2.05 a share, in line with the average Wall Street target of $1.90 a share. \n\n\n  Baxter also backed its projection for sales from continuing operations to be flat to up 1% for the year. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 08:21 ET (12:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}